HyperLp(a) and cvd

NYT

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952573/

https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/1743-7075-3-19

http://nejm.highwire.org/cgi/content/abstract/353/1/46



https://www.nytimes.com/2018/01/09/well/heart-risk-doctors-lipoprotein.html

https://clinicaltrials.gov/ct2/show/NCT01663402

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC108207/

Raised Lp(a) Slashed in CV Patients on Novel Antisense Agent: Top-Line Results - Medscape - Sep 24, 2018.

The CV risk is not only arterial.

It is a complex issue. I agree with the mandatory evolutionary vision of the prsence of Lp(a) in our blood. However  we have patients with thrombotic events especially in the venous system who have'nt the traditional factors of atherosclerosis and do have high Lp(a). The first step for them is to know the concentration of Lp(a) in their blood as this non-conventional marker is frequently ignored. The second step for them is to realize that  they necessitate a more agressive approach both preventively and for treatments. I will wait for the clinical results of this trial with interest.